达那唑治疗对C1抑制剂缺乏所致遗传性血管性水肿儿科患者生长的影响
[Effect of danazol treatment on growth in pediatric patients with hereditary angioedema due to C1-inhibitor deficiency].
作者信息
Kőhalmi Kinga Viktória, Veszeli Nóra, Luczay Andrea, Varga Lilian, Farkas Henriette
机构信息
III. Belgyógyászati Klinika, Országos Angiooedema Központ, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest, Kútvölgyi út 4., 1125.
I. Gyermekgyógyászati Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
出版信息
Orv Hetil. 2017 Aug;158(32):1269-1276. doi: 10.1556/650.2017.30806.
INTRODUCTION
Attenuated androgens are used for the prevention of angioedema attacks of hereditary angioedema with C1-inhibitor deficiency. After prepuberty, their use can lead to growth retardation.
AIM
We assessed the effect of danazol on the growth of pediatric patients with hereditary angioedema.
METHOD
In the retrospective study on 42 patients diagnosed with hereditary angioedema, we calculated the deviation from the mid-parental target height, and analyzed it against the gender, the dose and duration of danazol treatment administered before the age of 21 years and before the age of 16 years.
RESULTS
Regarding the deviation from the mid-parental target height, we did not find any significant difference between patients taking vs. not taking danazol, males vs. females taking danazol. The dose and the duration of danazol treatment did not influence that value neither before 21, nor before 16 years of age.
CONCLUSIONS
Our findings suggest that treatment with the lowest effective doses of danazol does not influence growth. Orv Hetil. 2017; 158(32): 1269-1276.
引言
减毒雄激素用于预防伴有C1抑制剂缺乏的遗传性血管性水肿发作。青春期前之后使用，可能导致生长发育迟缓。
目的
我们评估了达那唑对遗传性血管性水肿儿科患者生长发育的影响。
方法
在一项针对42例诊断为遗传性血管性水肿患者的回顾性研究中，我们计算了与父母平均身高目标值的偏差，并根据性别、21岁之前及16岁之前使用达那唑治疗的剂量和疗程进行分析。
结果
关于与父母平均身高目标值的偏差，我们发现服用达那唑与未服用达那唑的患者之间、服用达那唑的男性与女性之间没有显著差异。达那唑治疗的剂量和疗程在21岁之前以及16岁之前均未影响该数值。
结论
我们的研究结果表明，使用最低有效剂量的达那唑治疗不会影响生长发育。《匈牙利医学周报》2017年；158(32): 1269 - 1276。
Zotero 插件